These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 4631717)
41. Immunological monitoring of azathioprine treatment in multiple sclerosis patients. Salmaggi A; Corsini E; La Mantia L; Dufour A; Eoli M; Milanese C; Nespolo A J Neurol; 1997 Mar; 244(3):167-74. PubMed ID: 9050957 [TBL] [Abstract][Full Text] [Related]
42. [Aspects of the diagnostic criterions and the classification of the multiple sclerosis (author's transl)]. Meyer-Rienecker HJ; Olischer RM Fortschr Neurol Psychiatr Grenzgeb; 1974 Aug; 42(8):385-418. PubMed ID: 4496855 [No Abstract] [Full Text] [Related]
43. [Diagnostic measures in suspected multiple sclerosis]. Kunze K; Hartard C; Spitzer K Dtsch Med Wochenschr; 1989 Mar; 114(11):424-6. PubMed ID: 2651059 [No Abstract] [Full Text] [Related]
44. The immunosuppressive activity of azathioprine in serum and cerebrospinal fluid. Frick E Arzneimittelforschung; 1978; 28(3):473-4. PubMed ID: 580759 [TBL] [Abstract][Full Text] [Related]
46. A long-term double-blind controlled study on the effect of azathioprine in the treatment of multiple sclerosis. Minderhoud JM; Prange AJ; Luyckx GJ Clin Neurol Neurosurg; 1988; 90(1):25-8. PubMed ID: 3359729 [TBL] [Abstract][Full Text] [Related]
47. Multiple sclerosis: Genetic variability affects CNS IgG production in MS. Álvarez-Cermeño JC; Villar LM Nat Rev Neurol; 2015 Jun; 11(6):313-4. PubMed ID: 25868393 [No Abstract] [Full Text] [Related]
48. Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness. Patzold U; Pocklington P J Neurol; 1980; 223(2):97-117. PubMed ID: 6157007 [TBL] [Abstract][Full Text] [Related]
49. [Preliminary results of azathioprine treatment in disseminated sclerosis]. Cendrowski W Neurol Neurochir Pol; 1971; 5(6):829-35. PubMed ID: 5139005 [No Abstract] [Full Text] [Related]
54. Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients. Patzold U; Hecker H; Pocklington P J Neurol Sci; 1982 Jun; 54(3):377-94. PubMed ID: 7047686 [TBL] [Abstract][Full Text] [Related]
55. Azathioprine treatment in multiple sclerosis; pretreatment assessment of metaboliser status. Thomas FJ; Hughes TA; Anstey A J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):815. PubMed ID: 11430296 [No Abstract] [Full Text] [Related]
57. Double-blind controlled trial of azathioprine in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry; 1987 Oct; 50(10):1387. PubMed ID: 3316505 [No Abstract] [Full Text] [Related]
58. [Multiple sclerosis]. Schrader A Dtsch Med Wochenschr; 1977 Jun; 102(24):910-1. PubMed ID: 872760 [No Abstract] [Full Text] [Related]
59. The risk of cancer from azathioprine as a treatment for multiple sclerosis. Taylor L; Hughes RA; McPherson K Eur J Neurol; 2004 Feb; 11(2):141. PubMed ID: 14748776 [No Abstract] [Full Text] [Related]